Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn’s disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM). … Read the full story from the UCSD Newsroom
William Sandborn, MD, professor of clinical medicine and chief of the Division of Gastroenterology, was lead investigator in the Crohn’s disease study and co-investigator in the ulcerative colitis study. He is director of UC San Diego Health System’s Inflammatory Bowel Disease Center.
Sandborn joined the University of California, San Diego School of Medicine faculty from the Mayo Clinic in Rochester, Minnesota, in January 2011. There, he was Dorothy A. Adair Professor of Medicine, vice chair of the Mayo Clinic Division of Gastroenterology and Hepatology, and associate dean of research for Intellectual Property and Industry Relations.
Citations for the study reports:
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C and Parikh A for the GEMINI 2 Study Group. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med 2013; 369:711-721 August 22, 2013DOI: 10.1056/NEJMoa1215739. | Full text (UCSD only)
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, Van Assche G, Axler J, Kim H-J, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J and Parikh A for the GEMINI 1 Study Group. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2013; 369:699-710 August 22, 2013DOI: 10.1056/NEJMoa1215734. | Full text (UCSD only)
- Sandborn’s academic profile
- Sandborn’s clinical profile
- Related news stories: